http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021234471-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8672051461f957c1a49b10441f94584f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1214 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6835 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 |
| filingDate | 2021-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fc6b91c9b600bc80a3e5c617d03b073 |
| publicationDate | 2021-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021234471-A1 |
| titleOfInvention | An antibody fragment based antimicrobial conjugate selectively targeting pseudomonas |
| abstract | The present invention relates to a novel antibody fragment based antimicrobial conjugate selectively targeting Pseudomonas spp., preferably Pseudomonas aeruginosa, comprising of at least one antimicrobial peptide at one end of the conjugate preferably human Histatin-5; at least one antibody fragment at the other end of the conjugate, preferably a VHH targeting C4 decarboxylase transporterantigen of Pseudomonas aeruginosa; at least one protease cleavage sequence, preferably susceptible to cleavage by Pseudomonas aeruginosa specific virulent protease, Elastase B, and at least one flexible polypeptide linker in tandem with the protease cleavage sequence, and the protease cleavage sequence and the flexible polypeptide linker placedin between the antimicrobial peptide and antibody fragment. The antibody fragment based antimicrobial conjugatehas anin vitro MIC-99 against Pseudomonas aeruginosa of 0.5 µM, and MIC-50 less than 0.125 µM. Itcan be easily manipulated for generating next generation of conjugates in case of emergence of drug-resistant forms of the pathogen. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114404614-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114989254-A |
| priorityDate | 2020-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.